Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| G1 Therapeutics, Inc.GTHX · Entity 87413 | CFO | January 03, 2023 | January 05, 2023 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
G1 Therapeutics, Inc.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,188 |
Reported balance
After 2023-01-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 22,300 · Balance 60,188 F1: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2: Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Represents (i) 19,013 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 58,549 |
Reported balance
After 2023-01-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-01-04 · Sale · Disposed 1,639 · Balance 58,549 F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F5: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: Represents (i) 20,374 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 57,820 |
Reported balance
After 2023-01-05 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-01-05 · Sale · Disposed 729 · Balance 57,820 F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F7: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8: Represents (i) 21,020 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73 · Expires 2033-01-03 | Direct | 44,600 |
Reported balance
After 2023-01-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-03 · Grant · Acquired 44,600 · Balance 44,600 F9: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2: Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Represents (i) 19,013 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023.
F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: Represents (i) 20,374 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023.
F7: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: Represents (i) 21,020 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023.
F9: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 20:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 32,341 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001193125-26-294556 · ownership.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,341 Underlying: Common Stock · 32,341 shares Expires 2036-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:43 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000950170-25-093098 · ownership.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000950170-24-079037 · ownership.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2034-06-26 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 23:54 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $27.67 | $0.00 |
DisclosureSEC source: 0000950170-23-028725 · ownership.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 20:26 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 729 | $5.41 | $3,942.07 |
DisclosureSEC source: 0001562180-23-000255 · primarydocument.xml · nonDerivative · entry 3 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,820 F4 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F7 · price: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · balance_after: Represents (i) 21,020 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 20:26 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 1,639 | $5.58 | $9,138.41 |
DisclosureSEC source: 0001562180-23-000255 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,549 F4 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F5 · price: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Represents (i) 20,374 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 20:26 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to buy) · Derivative | 44,600 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001562180-23-000255 · primarydocument.xml · derivative · entry 4 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,600 Underlying: Common Stock · 44,600 shares Expires 2033-01-03 F9 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 20:26 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 22,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000255 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,188 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 19,013 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 11:30 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021804 · doc4.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 17:20 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 333 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-22-000956 · primarydocument.xml · derivative · entry 4 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 333 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 17:20 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $4.17 | $0.00 |
DisclosureSEC source: 0001562180-22-000956 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 2,000 shares Expires 2026-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 17:20 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 2,000 | $4.17 | $8,340.00 |
DisclosureSEC source: 0001562180-22-000956 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Represents (i) 17,638 shares of common stock; (ii) 8,250 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 17:20 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 333 | $3.72 | $1,238.76 |
DisclosureSEC source: 0001562180-22-000956 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Represents (i) 15,638 shares of common stock; (ii) 8,250 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 20:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 1,445 | $10.61 | $15,333.62 |
DisclosureSEC source: 0001562180-22-000306 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,555 F4 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F5 · price: The price represents the weighted average price with a low of $10.45 and a high of $10.76. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Represents (i) 15,305 shares of common stock; (ii) 8,250 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to buy) · Derivative | 53,000 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001562180-22-000306 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2032-01-03 F7 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000306 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2023 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 14,000 shares of common stock; (ii) 11,000 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 20:24 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000899243-21-028495 · doc4.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-07-14 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 16:54 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-001982 · primarydocument.xml · derivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333 Underlying: Common Stock · 3,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 16:54 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 3,000 | $3.72 | $11,160.00 |
DisclosureSEC source: 0001562180-21-001982 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Represents 14,000 shares of common stock and 11,000 restricted stock units Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 58,000 | $0.00 Strike: $18.07 | $0.00 |
DisclosureSEC source: 0000899243-21-000474 · doc4.xml · derivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2031-01-04 F4 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 4, 2022, with the remainder vesting in 36 equal installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-000474 · doc4.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 25% on January 4, 2022 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents 11,000 shares of common stock and 11,000 restricted stock units. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 07:00 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-20-002529 · primarydocument.xml · derivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 2,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 07:00 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 2,000 | $3.72 | $7,440.00 |
DisclosureSEC source: 0001562180-20-002529 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:14 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $21.08 | $0.00 |
DisclosureSEC source: 0001562180-20-001005 · primarydocument.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on February 06, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 16:58 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-20-000559 · primarydocument.xml · derivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 1,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 16:58 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 1,000 | $3.72 | $3,720.00 |
DisclosureSEC source: 0001562180-20-000559 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 21:58 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-19-004017 · primarydocument.xml · derivative · entry 2 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,333 Underlying: Common Stock · 2,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 21:58 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 2,000 | $3.72 | $7,440.00 |
DisclosureSEC source: 0001562180-19-004017 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2019 Filed May 10, 2019 16:26 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to buy) · Derivative | 50,000 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0001562180-19-002766 · primarydocument.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on May 8th, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 17, 2019 Filed Jan 17, 2019 17:52 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-19-000344 · primarydocument.xml · derivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 2,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 17, 2019 Filed Jan 17, 2019 17:52 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 2,000 | $3.72 | $7,440.00 |
DisclosureSEC source: 0001562180-19-000344 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 17:32 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.56 | $0.00 |
DisclosureSEC source: 0001562180-19-000093 · primarydocument.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 07, 2018 Filed Dec 7, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-18-004886 · primarydocument.xml · derivative · entry 5 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,333 Underlying: Common Stock · 2,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 07, 2018 Filed Dec 7, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 2,000 | $3.72 | $7,440.00 |
DisclosureSEC source: 0001562180-18-004886 · primarydocument.xml · nonDerivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-004886 · primarydocument.xml · derivative · entry 4 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666 Underlying: Common Stock · 750 shares Expires 2024-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $34.00 | $25,500.00 |
DisclosureSEC source: 0001562180-18-004886 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-004886 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 18:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-004453 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,416 Underlying: Common Stock · 750 shares Expires 2024-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 18:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $41.38 | $31,035.00 |
DisclosureSEC source: 0001562180-18-004453 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 18:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-004453 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:45 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-004208 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,166 Underlying: Common Stock · 750 shares Expires 2024-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:45 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $44.52 | $33,390.00 |
DisclosureSEC source: 0001562180-18-004208 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:45 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-004208 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-003854 · primarydocument.xml · derivative · entry 5 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,916 Underlying: Common Stock · 750 shares Expires 2024-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-18-003854 · primarydocument.xml · derivative · entry 4 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,333 Underlying: Common Stock · 2,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on December 16, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 2,000 | $3.72 | $7,440.00 |
DisclosureSEC source: 0001562180-18-003854 · primarydocument.xml · nonDerivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $59.60 | $44,700.00 |
DisclosureSEC source: 0001562180-18-003854 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-003854 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 06, 2018 Filed Aug 6, 2018 18:18 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-003499 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Underlying: Common Stock · 750 shares Expires 2024-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested Read SEC document |
| August 06, 2018 Filed Aug 6, 2018 18:18 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $50.79 | $38,092.50 |
DisclosureSEC source: 0001562180-18-003499 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.